Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BETAF-RED: Dose Reduction of Biktarvy in HIV
NCT05602506Phase 4Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Nov 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Viral efficacy of the reduction of BETAF regimen dose at 48 weeks. Started Nov 2022; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05602506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05602506.